Most of the focus in generative AI has been on text-based interfaces used to generate text, images, and more. The next wave appears to be voice, and it’s ...

Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

After hours: March 24 at 7:44:11 PM EDT Loading Chart for VRTX ...

Vertex AI is a fully-managed, unified AI development platform for building and using generative AI. This repository is designed to help you get started with Vertex AI. Whether you're new to Vertex AI ...